Clinical Trials Logo
  1. Home
  2. Body Dysmorphic Disorder
  3. NCT00245635

Fluoxetine in Pediatric Body Dysmorphic Disorder — FDA BDD  

Body Dysmorphic Disorder Clinical Trial

Official title:
Fluoxetine in Pediatric Body Dysmorphic Disorder

Clinical Trial Summary

This trial will study the effectiveness of the medication fluoxetine for children and adolescents ages 16 and younger with BDD who qualify.

Clinical Trial Description

BDD usually begins in childhood or adolescence, but its treatment in pediatric populations has not been investigated. Recent data suggests that adults with BDD may respond to serotonin reuptake inhibitors (SRIs) such as fluoxetine (Prozac). Preliminary findings from case reports suggest that SRIs may also be effective in the treatment of BDD in children and adolescents. This study is the first large-scale, double-blind, placebo-controlled medication trial of fluoxetine for children and adolescents with BDD. Participants should be aged 16 or younger. Participation in this trial will last approximately 14 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00245635
Study type Interventional
Source Montefiore Medical Center
Contact
Status Completed
Phase Phase 4
Start date November 2004
Completion date April 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT02635152 - Interpretation Bias Modification for Body Dysmorphic Disorder N/A
Completed NCT03673046 - Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD) N/A
Recruiting NCT05402475 - Online Cognitive Behavioural Therapy Intervention for Body Dysmorphic Disorder N/A
Withdrawn NCT02843451 - Milk Thistle in Body Dysmorphic Disorder Phase 2
Completed NCT02010619 - Internet Delivered CBT for Body Dysmorphic Disorder N/A
Completed NCT00842309 - D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder Early Phase 1
Completed NCT02808702 - Brain Correlates of Self-Focused Processing N/A
Completed NCT01002326 - Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder N/A
Active, not recruiting NCT01075672 - Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals N/A
Completed NCT02671266 - Oxytocin Administration in BDD and OCD Phase 2
Completed NCT01038128 - An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder N/A
Completed NCT01398865 - Escitalopram Neuroimaging Supplement N/A
Completed NCT00265109 - Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Phase 4
Recruiting NCT04373629 - Perceptual Abnormalities and Their Malleability in BDD N/A
Completed NCT01453439 - Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder N/A
Completed NCT00871143 - Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD) N/A
Completed NCT00106223 - Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder N/A
Active, not recruiting NCT00211809 - CBT as an Adjunct to SRIs in the Treatment of BDD Phase 4